olmesartan medoxomil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 1985 144689-63-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • olmesartan medoxomil
  • olmetec
  • CS-866
  • CS866
Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.
  • Molecular weight: 558.60
  • Formula: C29H30N6O6
  • CLOGP: 2.66
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 2
  • TPSA: 154.34
  • ALOGS: -4.88
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.02 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 26 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 25, 2002 FDA DAIICHI SANKYO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malabsorption 460.26 10.33 156 37710 3627 46644569
Sprue-like enteropathy 452.12 10.33 98 37768 345 46647851
Intestinal villi atrophy 147.54 10.33 33 37833 139 46648057
Acute kidney injury 146.63 10.33 472 37394 235383 46412813
Hyperkalaemia 100.04 10.33 161 37705 50548 46597648
Hyponatraemia 98.64 10.33 239 37627 101093 46547103
Dehydration 79.53 10.33 297 37569 159243 46488953
Blood pressure increased 70.93 10.33 245 37621 126421 46521775
Renal failure 59.52 10.33 215 37651 113379 46534817
Completed suicide 56.18 10.33 24 37842 145896 46502300
Coeliac disease 55.02 10.33 46 37820 7115 46641081
Hypertensive crisis 54.33 10.33 61 37805 13554 46634642
Colitis microscopic 54.32 10.33 44 37822 6512 46641684
Drug ineffective 52.50 10.33 329 37537 677509 45970687
Hypertension 51.42 10.33 303 37563 196053 46452143
Diarrhoea 48.64 10.33 678 37188 558924 46089272
Dizziness 47.81 10.33 453 37413 339961 46308235
Treatment failure 45.34 10.33 10 37856 93077 46555119
Device related thrombosis 44.04 10.33 21 37845 1206 46646990
Rheumatoid arthritis 43.80 10.33 80 37786 240135 46408061
Bradycardia 42.21 10.33 134 37732 66164 46582032
Death 40.68 10.33 138 37728 335410 46312786
Blood urea increased 40.09 10.33 73 37793 25279 46622917
Metabolic acidosis 39.32 10.33 93 37773 38687 46609509
Toxicity to various agents 37.29 10.33 72 37794 211694 46436502
Gallbladder polyp 36.54 10.33 16 37850 753 46647443
Hypertensive emergency 35.80 10.33 20 37846 1598 46646598
Pancreatic toxicity 32.66 10.33 7 37859 23 46648173
Renal impairment 32.55 10.33 133 37733 74239 46573957
Maternal exposure during pregnancy 31.97 10.33 22 37844 102527 46545669
Cerebral infarction 31.66 10.33 63 37803 23303 46624893
Syncope 31.55 10.33 168 37698 104635 46543561
Blood pressure inadequately controlled 31.18 10.33 27 37839 4379 46643817
Infusion related reaction 31.17 10.33 22 37844 101186 46547010
Asthenia 30.67 10.33 386 37480 310689 46337507
Synovitis 28.86 10.33 7 37859 61068 46587128
Lower respiratory tract infection 28.75 10.33 5 37861 55084 46593112
Exposure during pregnancy 27.83 10.33 28 37838 108184 46540012
Weight decreased 27.75 10.33 277 37589 210572 46437624
Pemphigus 26.22 10.33 3 37863 45271 46602925
Blood pressure decreased 25.63 10.33 103 37763 57056 46591140
Microvillous inclusion disease 25.45 10.33 5 37861 9 46648187
Off label use 25.00 10.33 193 37673 379648 46268548
Renal disorder 24.91 10.33 62 37804 26624 46621572
Systemic lupus erythematosus 24.62 10.33 11 37855 65169 46583027
Drug intolerance 24.16 10.33 52 37814 146997 46501199
Therapeutic product effect decreased 24.08 10.33 19 37847 82582 46565614
Blood creatinine increased 24.03 10.33 124 37742 76279 46571917
Collagen disorder 23.35 10.33 8 37858 192 46648004
Hypokalaemia 23.09 10.33 136 37730 87888 46560308
Oligohydramnios 22.69 10.33 25 37841 5440 46642756
Normocytic anaemia 22.30 10.33 13 37853 1126 46647070
Product administration error 21.93 10.33 49 37817 19632 46628564
Chronic kidney disease 21.92 10.33 78 37788 40793 46607403
Anti-transglutaminase antibody increased 21.70 10.33 4 37862 4 46648192
Normochromic anaemia 21.48 10.33 8 37858 246 46647950
Decreased appetite 21.46 10.33 246 37620 193590 46454606
Large intestine polyp 21.31 10.33 29 37837 7832 46640364
Lymphocytic infiltration 20.71 10.33 11 37855 795 46647401
Gastritis 20.53 10.33 68 37798 34310 46613886
Hepatic function abnormal 20.48 10.33 68 37798 34353 46613843
Enteritis 19.97 10.33 26 37840 6729 46641467
Diverticulum 19.95 10.33 34 37832 11172 46637024
Contraindicated product administered 19.09 10.33 22 37844 79925 46568271
Gastrointestinal ischaemia 18.80 10.33 7 37859 215 46647981
Hypoalbuminaemia 18.39 10.33 31 37835 10096 46638100
Hypotension 18.16 10.33 277 37589 232312 46415884
Angiosclerosis 18.05 10.33 4 37862 16 46648180
Product substitution issue 17.40 10.33 38 37828 14993 46633203
Liver disorder 17.40 10.33 68 37798 37178 46611018
Spleen congestion 17.17 10.33 6 37860 153 46648043
Product use issue 16.79 10.33 32 37834 94612 46553584
Infection 16.79 10.33 54 37812 133538 46514658
Burn oesophageal 16.71 10.33 6 37860 166 46648030
Oedema peripheral 15.61 10.33 198 37668 159508 46488688
Autoimmune enteropathy 15.42 10.33 3 37863 5 46648191
Hyperuricaemia 15.28 10.33 19 37847 4698 46643498
Gastrooesophageal reflux disease 15.27 10.33 108 37758 74236 46573960
Therapeutic product effect incomplete 15.15 10.33 25 37841 78128 46570068
Atrial tachycardia 15.02 10.33 13 37853 2107 46646089
Gastritis erosive 14.96 10.33 20 37846 5310 46642886
Haemorrhoids 14.84 10.33 41 37825 18736 46629460
Hypoglycaemic coma 14.73 10.33 14 37852 2560 46645636
Rhabdomyolysis 14.58 10.33 70 37796 41839 46606357
Hospitalisation 14.54 10.33 18 37848 63367 46584829
Aortic valve calcification 14.39 10.33 7 37859 420 46647776
Febrile neutropenia 14.29 10.33 35 37831 94592 46553604
Confabulation 14.08 10.33 6 37860 264 46647932
Pain 14.00 10.33 288 37578 476660 46171536
Leukocyturia 13.91 10.33 9 37857 939 46647257
Aortic dissection 13.86 10.33 11 37855 1581 46646615
Foetal exposure during pregnancy 13.62 10.33 4 37862 30743 46617453
Wound 13.58 10.33 9 37857 42793 46605403
Atrial fibrillation 13.55 10.33 136 37730 103454 46544742
Hiatus hernia 13.52 10.33 39 37827 18263 46629933
Hypocalcaemia 13.41 10.33 50 37816 26735 46621461
Putamen haemorrhage 13.33 10.33 5 37861 157 46648039
Device expulsion 13.32 10.33 3 37863 27539 46620657
Azotaemia 13.26 10.33 17 37849 4334 46643862
Heart rate irregular 13.15 10.33 39 37827 18552 46629644
Oesophagitis 13.04 10.33 32 37834 13619 46634577
Pregnancy 13.04 10.33 3 37863 27134 46621062
Varicose vein 12.99 10.33 17 37849 4421 46643775
Nail disorder 12.81 10.33 23 37843 7873 46640323
Bezoar 12.77 10.33 10 37856 1409 46646787
Prerenal failure 12.66 10.33 10 37856 1427 46646769
Pneumonia 12.64 10.33 222 37644 376098 46272098
Sopor 12.54 10.33 40 37826 19788 46628408
Polyp 12.49 10.33 18 37848 5125 46643071
Product use in unapproved indication 12.40 10.33 35 37831 90238 46557958
Neutropenia 12.32 10.33 67 37799 143137 46505059
Anuria 12.22 10.33 28 37838 11403 46636793
Joint swelling 12.04 10.33 82 37784 165991 46482205
Hepatorenal failure 11.87 10.33 7 37859 619 46647577
Lymphocyte stimulation test positive 11.83 10.33 7 37859 623 46647573
Purpura senile 11.78 10.33 7 37859 628 46647568
Pharyngeal haematoma 11.78 10.33 3 37863 24 46648172
Hair texture abnormal 11.74 10.33 13 37853 2843 46645353
Anti-insulin antibody positive 11.71 10.33 4 37862 95 46648101
Acquired oesophageal web 11.55 10.33 5 37861 229 46647967
Skin exfoliation 11.44 10.33 55 37811 32883 46615313
Hepatitis alcoholic 11.23 10.33 4 37862 108 46648088
Anaemia 11.19 10.33 279 37587 255500 46392696
Blood glucose increased 11.15 10.33 98 37768 71915 46576281
Brain stem haemorrhage 10.94 10.33 7 37859 716 46647480
Hypoperfusion 10.78 10.33 9 37857 1388 46646808
Hyperlactacidaemia 10.73 10.33 11 37855 2204 46645992
Musculoskeletal stiffness 10.71 10.33 42 37824 97951 46550245
Intentional overdose 10.63 10.33 23 37843 64921 46583275
Blood triglycerides increased 10.60 10.33 27 37839 11756 46636440
Mucosa vesicle 10.54 10.33 3 37863 38 46648158
Withdrawal hypertension 10.33 10.33 4 37862 137 46648059

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malabsorption 376.23 11.44 117 26371 1870 29924120
Sprue-like enteropathy 354.39 11.44 78 26410 269 29925721
Intestinal villi atrophy 86.79 11.44 21 26467 120 29925870
Gastrointestinal disorder 77.03 11.44 109 26379 28028 29897962
Blood pressure increased 68.00 11.44 177 26311 71751 29854239
Coeliac disease 64.05 11.44 23 26465 582 29925408
Cerebral infarction 61.84 11.44 95 26393 26278 29899712
Renal impairment 60.85 11.44 188 26300 83996 29841994
Death 58.58 11.44 145 26343 357138 29568852
Hepatic function abnormal 56.94 11.44 119 26369 41826 29884164
Toxicity to various agents 53.32 11.44 47 26441 177136 29748854
Hyperkalaemia 49.15 11.44 149 26339 65861 29860129
Interstitial lung disease 47.78 11.44 139 26349 60058 29865932
Blood pressure decreased 46.68 11.44 118 26370 46957 29879033
Hyperuricaemia 46.45 11.44 44 26444 7350 29918640
Hypertension 45.48 11.44 220 26268 121134 29804856
Colitis microscopic 38.51 11.44 22 26466 1681 29924309
Syncope 37.81 11.44 162 26326 84741 29841249
Diarrhoea 37.40 11.44 455 26033 333648 29592342
Loss of consciousness 33.46 11.44 149 26339 79226 29846764
Intestinal intraepithelial lymphocytes increased 32.56 11.44 6 26482 5 29925985
Completed suicide 31.60 11.44 25 26463 99467 29826523
Dermatitis infected 31.22 11.44 9 26479 109 29925881
Dehydration 30.34 11.44 200 26288 123339 29802651
Dizziness 28.93 11.44 281 26207 194628 29731362
Gastrointestinal erosion 28.23 11.44 11 26477 351 29925639
Microvillous inclusion disease 27.83 11.44 7 26481 48 29925942
Hypotension 27.28 11.44 284 26204 200281 29725709
Product use in unapproved indication 26.75 11.44 16 26472 73677 29852313
Lymphangiectasia intestinal 26.70 11.44 5 26483 5 29925985
Pancreatic neoplasm 26.11 11.44 14 26474 945 29925045
Hospitalisation 26.09 11.44 4 26484 44315 29881675
Acute kidney injury 25.97 11.44 362 26126 273480 29652510
Hyperkinetic heart syndrome 25.94 11.44 8 26480 124 29925866
Hypertensive crisis 25.29 11.44 34 26454 8323 29917667
Off label use 25.28 11.44 124 26364 249166 29676824
Weight decreased 23.56 11.44 220 26268 150701 29775289
Neutropenia 23.52 11.44 49 26439 128491 29797499
Liver disorder 22.95 11.44 68 26420 29654 29896336
Atrophy 22.39 11.44 13 26475 1024 29924966
Renal disorder 22.20 11.44 58 26430 23526 29902464
Palmar-plantar erythrodysaesthesia syndrome 19.94 11.44 42 26446 14828 29911162
Hypokalaemia 19.48 11.44 92 26396 50100 29875890
Transient aphasia 18.32 11.44 6 26482 114 29925876
Renal failure 18.15 11.44 184 26304 128782 29797208
Enterocolitis viral 18.12 11.44 5 26483 51 29925939
Tropical sprue 18.10 11.44 3 26485 0 29925990
Borderline personality disorder 17.60 11.44 8 26480 377 29925613
Plasma cell myeloma 17.52 11.44 13 26475 53449 29872541
Blood pressure inadequately controlled 17.50 11.44 16 26472 2554 29923436
Product administration error 17.44 11.44 39 26449 14338 29911652
Chronic kidney disease 17.44 11.44 73 26415 37765 29888225
Immune-mediated myositis 17.42 11.44 12 26476 1273 29924717
Gastrooesophageal reflux disease 17.09 11.44 65 26423 32190 29893800
Pulmonary hypoplasia 16.73 11.44 8 26480 423 29925567
Anaplastic astrocytoma 16.45 11.44 6 26482 159 29925831
Drug abuse 16.11 11.44 30 26458 82042 29843948
Autoimmune enteropathy 16.09 11.44 4 26484 26 29925964
Cerebral haemorrhage 15.59 11.44 64 26424 32823 29893167
Drug ineffective 15.56 11.44 210 26278 340177 29585813
Large intestine polyp 15.48 11.44 24 26464 6685 29919305
Prerenal failure 15.46 11.44 13 26475 1858 29924132
Sinus node dysfunction 15.41 11.44 18 26470 3825 29922165
Colon cancer 15.35 11.44 27 26461 8345 29917645
Anaemia 15.10 11.44 263 26225 207729 29718261
Gastroenteritis 15.00 11.44 35 26453 13231 29912759
Treatment failure 14.89 11.44 6 26482 34673 29891317
Haemorrhoids 14.80 11.44 33 26455 12108 29913882
Febrile neutropenia 14.64 11.44 47 26441 106646 29819344
Hypoalbuminaemia 14.49 11.44 31 26457 11061 29914929
Decreased appetite 14.49 11.44 199 26289 149711 29776279
Peripheral venous disease 14.44 11.44 13 26475 2035 29923955
Product odour abnormal 14.24 11.44 8 26480 592 29925398
Collagen disorder 14.21 11.44 5 26483 119 29925871
Hypertensive emergency 14.16 11.44 9 26479 835 29925155
Tinea pedis 13.91 11.44 10 26478 1136 29924854
Renal cyst haemorrhage 13.35 11.44 5 26483 143 29925847
Gastric cancer 13.27 11.44 19 26469 4931 29921059
Oligohydramnios 12.79 11.44 6 26482 304 29925686
Echocardiogram abnormal 12.76 11.44 8 26480 724 29925266
Helicobacter test positive 12.73 11.44 7 26481 497 29925493
Peripheral arterial occlusive disease 12.65 11.44 19 26469 5149 29920841
Intestinal ulcer perforation 12.57 11.44 3 26485 16 29925974
Blood creatinine increased 12.19 11.44 129 26359 91246 29834744
Gastrointestinal mucosa hyperaemia 12.16 11.44 5 26483 184 29925806
Pancytopenia 11.99 11.44 37 26451 85015 29840975
Blood creatine phosphokinase abnormal 11.94 11.44 5 26483 193 29925797
Rectal ulcer haemorrhage 11.84 11.44 4 26484 84 29925906
Diabetic nephropathy 11.50 11.44 11 26477 1858 29924132
Atrioventricular block 11.47 11.44 22 26466 7260 29918730

Pharmacologic Action:

SourceCodeDescription
ATC C09CA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
Angiotensin II receptor blockers (ARBs), plain
ATC C09DA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and diuretics
ATC C09DB02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC C09DX03 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
FDA MoA N0000000070 Angiotensin 2 Receptor Antagonists
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:61016 angiotensin receptor antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Azotemia contraindication 445009001
Severe Aortic Valve Stenosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.25 acidic
pKa2 5.76 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST IC50 8.10 IUPHAR CHEMBL
Type-1 angiotensin II receptor GPCR IC50 8.09 CHEMBL

External reference:

IDSource
4021345 VUID
N0000179505 NUI
D01204 KEGG_DRUG
144689-24-7 SECONDARY_CAS_RN
4021344 VANDF
4021345 VANDF
C0386394 UMLSCUI
C1098320 UMLSCUI
CHEBI:31932 CHEBI
CHEBI:48416 CHEBI
OLM PDB_CHEM_ID
CHEMBL1200692 ChEMBL_ID
CHEMBL1516 ChEMBL_ID
D000068557 MESH_DESCRIPTOR_UI
130881 PUBCHEM_CID
C437965 MESH_SUPPLEMENTAL_RECORD_UI
7787 INN_ID
8612 INN_ID
6M97XTV3HD UNII
8W1IQP3U10 UNII
158781 PUBCHEM_CID
591 IUPHAR_LIGAND_ID
DB00275 DRUGBANK_ID
118463 RXNORM
16642 MMSL
245076 MMSL
d04801 MMSL
009634 NDDF
009635 NDDF
385540001 SNOMEDCT_US
412259001 SNOMEDCT_US
412260006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5002 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5003 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5004 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5005 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5006 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-248 TABLET 5 mg ORAL ANDA 21 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-249 TABLET 20 mg ORAL ANDA 21 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-250 TABLET 40 mg ORAL ANDA 21 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 13668-251 TABLET 20 mg ORAL ANDA 20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 13668-252 TABLET 40 mg ORAL ANDA 20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 13668-253 TABLET 40 mg ORAL ANDA 20 sections
Amlodipine and Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 2 13668-311 TABLET 40 mg ORAL ANDA 21 sections
Amlodipine and Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 2 13668-312 TABLET 20 mg ORAL ANDA 21 sections
Amlodipine and Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 2 13668-313 TABLET 40 mg ORAL ANDA 21 sections
Amlodipine and Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 2 13668-324 TABLET 20 mg ORAL ANDA 21 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/25 mg HUMAN PRESCRIPTION DRUG LABEL 3 13668-382 TABLET 40 mg ORAL ANDA 25 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/12.5 mg HUMAN PRESCRIPTION DRUG LABEL 3 13668-383 TABLET 40 mg ORAL ANDA 25 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/25 mg HUMAN PRESCRIPTION DRUG LABEL 3 13668-385 TABLET 40 mg ORAL ANDA 25 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/12.5 mg HUMAN PRESCRIPTION DRUG LABEL 3 13668-386 TABLET 40 mg ORAL ANDA 25 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 20/5/12.5 mg HUMAN PRESCRIPTION DRUG LABEL 3 13668-397 TABLET 20 mg ORAL ANDA 25 sections
olmesartan medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 16729-320 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
olmesartan medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 16729-321 TABLET, FILM COATED 20 mg ORAL ANDA 27 sections
olmesartan medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 16729-322 TABLET, FILM COATED 40 mg ORAL ANDA 27 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 16729-366 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 16729-367 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 16729-368 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Amlodipine besylate and Olmesartan medoxomil Human Prescription Drug Label 2 27241-083 TABLET 20 mg ORAL ANDA 26 sections
Amlodipine besylate and Olmesartan medoxomil Human Prescription Drug Label 2 27241-084 TABLET 40 mg ORAL ANDA 26 sections
Amlodipine besylate and Olmesartan medoxomil Human Prescription Drug Label 2 27241-085 TABLET 20 mg ORAL ANDA 26 sections
Amlodipine besylate and Olmesartan medoxomil Human Prescription Drug Label 2 27241-086 TABLET 40 mg ORAL ANDA 26 sections